PLGA in situ implants formed by phase inversion: Critical physicochemical parameters to modulate drug release

Journal of Controlled Release

Volumn 172, Issue 1, 2013, Pages 292-304

  Parent, Marianne ^a   Nouvel, Cécile ^b,c   Koerber, Martin ^d   Sapin, Anne ^a   Maincent, Philippe ^a   Boudier, Ariane ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ DE LORRAINE   (France)

^c CNRS   (France)

^d FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Drug delivery system; In situ forming implants; In situ precipitation; Phase separation; PLGA; Solvent exchange

Indexed keywords

DRUG DELIVERY SYSTEM; IN-SITU FORMING; IN-SITU PRECIPITATION; PLGA; SOLVENT EXCHANGES;

DRUG DELIVERY; PHASE SEPARATION; POLYMERS;

COPOLYMERS;

ACETYLSALICYLIC ACID; BETAMETHASONE; BUPIVACAINE; CALCITONIN; CISPLATIN; DOXYCYCLINE; FENRETINIDE; HALOPERIDOL; HUMAN GROWTH HORMONE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; INSULIN; IVERMECTIN; KETOPROFEN; LEUPRORELIN; LEVONORGESTREL; NALTREXONE; PALIPERIDONE; POLYGLACTIN; POLYMER; RISPERIDONE; ROSIGLITAZONE; SECNIDAZOLE; TESTOSTERONE; THYMOSIN ALPHA1; TINIDAZOLE; VINPOCETINE;

DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG IMPLANT; DRUG RELEASE; HUMAN; NONHUMAN; PHASE SEPARATION; PHASE TRANSITION; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; REPRODUCIBILITY; REVIEW; SUSTAINED DRUG RELEASE; THERMODYNAMICS; TOXICITY;

2-PYRROLIDONE; 2P; BA; BB; BENZYL ALCOHOL; BENZYL BENZOATE; DIMETHYL SULFOXIDE; DMSO; DRUG DELIVERY SYSTEM; EA; ETHYL ACETATE; GA; GENERALLY RECOGNIZED AS SAFE; GLYCOLIDE; GRAS; IIG; IN SITU FORMING IMPLANTS; IN SITU FORMING MICROPARTICLES; IN SITU PRECIPITATION; INACTIVE INGREDIENT; ISI; ISM; LA; LACTIDE; LD50; LETHAL DOSE 50; N-METHYL-2-PYRROLIDONE; NMP; PDLA; PEO; PGA; PHASE SEPARATION; PLA; PLGA; PLLA; POLY(D,L-LACTIDE); POLY(ETHYLENE OXIDE); POLY(GLYCOLIDE); POLY(L-LACTIDE); POLY(LACTIDE); POLY(LACTIDE-CO-GLYCOLIDE); POLY(PROPYLENE OXIDE); POLYVINYLPYRROLIDONE; PPO; PVP; SOLVENT EXCHANGE; TA; TRIACETIN;

ANIMALS; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; HUMANS; LACTIC ACID; PHARMACEUTICAL PREPARATIONS; PHASE TRANSITION; POLYGLYCOLIC ACID; PROSTHESES AND IMPLANTS;

EID: 84884302005     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.08.024     Document Type: Review

References (115)

1. L.R. Fogueri, and S. Singh Smart polymers for controlled delivery of proteins and peptides: a review of patents Recent Pat. Drug Deliv. Formul. 3 2009 40 48
2. W.M. Obeidat Recent patents review in microencapsulation of pharmaceuticals using the emulsion solvent removal methods Recent Pat. Drug Deliv. Formul. 3 2009 178 192
3. S. Mao, C. Guo, Y. Shi, and L.C. Li Recent advances in polymeric microspheres for parenteral drug delivery-part 1 Expert Opin. Drug Deliv. 9 2012 1161 1176
4. P. Couvreur, and C. Vauthier Nanotechnology: intelligent design to treat complex disease Pharm. Res. 23 2006 1417 1450
5. C.B. Packhaeuser, J. Schnieders, C.G. Oster, and T. Kissel In situ forming parenteral drug delivery systems: an overview Eur. J. Pharm. Biopharm. 58 2004 445 455
6. A. Hatefi, and B. Amsden Biodegradable injectable in situ forming drug delivery systems J. Control. Release 80 2002 9 28
7. S. Kempe, and K. Mäder In situ forming implants - an attractive formulation principle for parenteral depot formulations J. Control. Release 161 2012 668 679
8. P. Agarwal, and I.D. Rupenthal Injectable implants for the sustained release of protein and peptide drugs Drug Discov. Today 18 2013 337 349
9. R.L. Dunn, J.P. English, D.R. Cowsar, D.P. Vanderbilt, Biodegradable in situ forming implants and methods of producing the same, US Patent No. 4 938 763, 1990.
10. R.L. Dunn, J.P. English, D.R. Cowsar, D.P. Vanderbilt, Biodegradable in-situ forming implants and methods of producing the same, US Patent No. 5 278 201, 1994.
11. O. Sartor Eligard: leuprolide acetate in a novel sustained-release delivery system Urology 61 2003 25 31
12. G.L. Southard, R.L. Dunn, and S. Garrett The drug delivery and biomaterial attributes of the ATRIGEL technology in the treatment of periodontal disease Expert Opin. Investig. Drugs 7 1998 1483 1491
13. K.P. Andriano, B. Chandrashekar, K. McEnery, R.L. Dunn, K. Moyer, C.M. Balliu, K.M. Holland, S. Garrett, and W.E. Huffer Preliminary in vivo studies on the osteogenic potential of bone morphogenetic proteins delivered from an absorbable puttylike polymer matrix J. Biomed. Mater. Res. 53 2000 36 43
14. K.J. Brodbeck, J.R. DesNoyer, and A.J. McHugh Phase inversion dynamics of PLGA solutions related to drug delivery. Part II. The role of solution thermodynamics and bath-side mass transfer J. Control. Release 62 1999 333 344
15. F.-A. Chen, M.A. Kuriakose, M.-X. Zhou, M.D. DeLacure, and R.L. Dunn Biodegradable polymer-mediated intratumoral delivery of cisplatin for treatment of human head and neck squamous cell carcinoma in a chimeric mouse model Head Neck 25 2003 554 560
16. W.S. Dernell, R.C. Straw, S.J. Withrow, B.E. Powers, S.M. Fujita, G.S. Yewey, K.F. Joseph, R.L. Dunn, S.L. Whitman, and G.L. Southard Apparent interaction of dimethyl sulfoxide with cisplatin released from polymer delivery devices injected subcutaneously in dogs J. Drug Target. 5 1998 391 396
17. C. Wischke, Y. Zhang, S. Mittal, and S.P. Schwendeman Development of PLGA-based injectable delivery systems for hydrophobic fenretinide Pharm. Res. 27 2010 2063 2074
18. K.J. Brodbeck, S. Pushpala, and A.J. McHugh Sustained release of human growth hormone from PLGA solution depots Pharm. Res. 16 1999 1825 1829
19. S. Chen, and J. Singh In vitro release of levonorgestrel from phase sensitive and thermosensitive smart polymer delivery systems Pharm. Dev. Technol. 10 2005 319 325
20. S. Chen, and J. Singh Controlled delivery of testosterone from smart polymer solution based systems: in vitro evaluation Int. J. Pharm. 295 2005 183 190
21. S. Prabhu, L.P. Tran, and G.V. Betageri Effect of co-solvents on the controlled release of calcitonin polypeptide from in situ biodegradable polymer implants Drug Deliv. 12 2005 393 398
22. M. Rafienia, S.H. Emami, H. Mirzadeh, H. Mobedi, and S. Karbasi Influence of poly (lactide-co-glycolide) type and gamma irradiation on the betamethasone acetate release from the in situ forming systems Curr. Drug Deliv. 6 2009 184 191
23. Q. Liu, H. Zhang, G. Zhou, S. Xie, H. Zou, Y. Yu, G. Li, D. Sun, G. Zhang, Y. Lu, and Y. Zhong In vitro and in vivo study of thymosin alpha1 biodegradable in situ forming poly(lactide-co-glycolide) implants Int. J. Pharm. 397 2010 122 129
24. R.E. Eliaz, D. Wallach, and J. Kost Delivery of soluble tumor necrosis factor receptor from in-situ forming PLGA implants: in-vivo Pharm. Res. 17 2000 1546 1550
25. J.A. Camargo, A. Sapin, C. Nouvel, D. Daloz, M. Leonard, F. Bonneaux, J.L. Six, and P. Maincent Injectable PLA-based in situ forming implants for controlled release of Ivermectin a BCS Class II drug: solvent selection based on physico-chemical characterization Drug Dev. Ind. Pharm. 39 2013 146 155
26. H.A. Gad, M.A. El-Nabarawi, and S.S. Abd El-Hady Formulation and evaluation of PLA and PLGA in situ implants containing secnidazole and/or doxycycline for treatment of periodontitis AAPS Pharm. Sci. Tech. 9 2008 878 884
27. Y. Qin, M. Yuan, L. Li, W. Li, and J. Xue Formulation and evaluation of in situ forming PLA implant containing tinidazole for the treatment of periodontitis J. Biomed. Mater. Res. B Appl. Biomater. 100 2012 2197 2202
28. D.N. Kapoor, O.P. Katare, and S. Dhawan In situ forming implant for controlled delivery of an anti-HIV fusion inhibitor Int. J. Pharm. 426 2012 132 143
29. Y. Tang, and J. Singh Controlled delivery of aspirin: effect of aspirin on polymer degradation and in vitro release from PLGA based phase sensitive systems Int. J. Pharm. 357 2008 119 125
30. S.-H. Wang, L.-N. Yin, Z.-H. Liang, S.-J. Lu, and S. Zeng Stereoselective behavior of a novel biodegradable racemic ketoprofen injectable implant in rats Chirality 19 2007 769 774
31. H. Kranz, E. Yilmaz, G.A. Brazeau, and R. Bodmeier In vitro and in vivo drug release from a novel in situ forming drug delivery system Pharm. Res. 25 2008 1347 1354
32. T.A. Ahmed, H.M. Ibrahim, F. Ibrahim, A.M. Samy, A. Kaseem, M.T.H. Nutan, and M.D. Hussain Development of biodegradable in situ implant and microparticle injectable formulations for sustained delivery of haloperidol J. Pharm. Sci. 101 2012 3753 3762
33. S. Dong, S. Wang, C. Zheng, W. Liang, and Y. Huang An in situ-forming, solid lipid/PLGA hybrid implant for long-acting antipsychotics Soft Matter 7 2011 5873 5878
34. L. Wang, A. Wang, X. Zhao, X. Liu, D. Wang, F. Sun, and Y. Li Design of a long-term antipsychotic in situ forming implant and its release control method and mechanism Int. J. Pharm. 427 2012 284 292
35. R. Bakhshi, E. Vasheghani-Farahani, H. Mobedi, A. Jamshidi, and M. Khakpour The effect of additives on naltrexone hydrochloride release and solvent removal rate from an injectable in situ forming PLGA implant Polym. Adv. Technol. 17 2006 354 359
36. M. Madhu, L. Shaila, and B.J. Anwar Biodegradable injectable implants systems for sustained delivery using poly(lactide-co-glycolide) copolymers Int. J. Pharm. Pharm. Sci. Suppl. 1 2009 103 107
37. S. Dhawan, R. Kapil, and D.N. Kapoor Development and evaluation of in situ gel-forming system for sustained delivery of insulin J. Biomater. Appl. 25 2011 699 720
38. R.E. Eliaz, and F.C. Szoka Robust and prolonged gene expression from injectable polymeric implants Gene Ther. 9 2002 1230 1237
39. O. Jeon, M. Krebs, and E. Alsberg Controlled and sustained gene delivery from injectable, porous PLGA scaffolds J. Biomed. Mater. Res. A 98 2011 72 79
40. T.-H. Young, and L.-W. Chen Pore formation mechanism of membranes from phase inversion process Desalination 103 1995 233 247
41. P.D. Graham, K.J. Brodbeck, and A.J. McHugh Phase inversion dynamics of PLGA solutions related to drug delivery J. Control. Release 58 1999 233 245
42. L. Solorio, B.M. Babin, R.B. Patel, J. Mach, N. Azar, and A.A. Exner Noninvasive characterization of in situ forming implants using diagnostic ultrasound J. Control. Release 143 2010 183 190
43. W.I. Higuchi Analysis of data on medicament release from ointments J. Pharm. Sci. 51 1962 802 804
44. C.G. Pitt The controlled parenteral delivery of polypeptides and proteins Int. J. Pharm. 59 1990 173 196
45. S.A. McKelvey, and W.J. Koros Phase separation, vitrification, and the manifestation of macrovoids in polymeric asymmetric membranes J. Membr. Sci 112 1996 29 39
46. X. Luan, and R. Bodmeier Influence of the poly(lactide-co-glycolide) type on the leuprolide release from in situ forming microparticle systems J. Control. Release 110 2006 266 272
47. C. Raman, C. Berkland, K. Kim, and D.W. Pack Modeling small-molecule release from PLG microspheres: effects of polymer degradation and nonuniform drug distribution J. Control. Release 103 2005 149 158
48. H. Okada One- and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate Adv. Drug Deliv. Rev. 28 1997 43 70
49. N. Faisant, J. Siepmann, and J.P. Benoit PLGA-based microparticles: elucidation of mechanisms and a new, simple mathematical model quantifying drug release Eur. J. Pharm. Sci. 15 2002 355 366
50. S. Fredenberg, M. Wahlgren, M. Reslow, and A. Axelsson The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems - a review Int. J. Pharm. 415 2011 34 52
51. A. Göpferich Mechanisms of polymer degradation and erosion Biomaterials 17 1996 103 114
52. S.J. De Jong, E.R. Arias, D.T.S. Rijkers, C.F. van Nostrum, J.J. Kettenes-van den Bosch, and W.E. Hennink New insights into the hydrolytic degradation of poly(lactic acid): participation of the alcohol terminus Polymer 42 2001 2795 2802
53. M. Körber PLGA erosion: solubility- or diffusion-controlled? Pharm. Res. 27 2010 2414 2420
54. F. von Burkersroda, L. Schedl, and A. Göpferich Why degradable polymers undergo surface erosion or bulk erosion Biomaterials 23 2002 4221 4231
55. I. Grizzi, H. Garreau, S. Li, and M. Vert Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence Biomaterials 16 1995 305 311
56. S.M. Li, and M. Vert Morphological changes resulting from the hydrolytic degradation of stereocopolymers derived from l- and DL-Lactides Macromolecules 27 1994 3107 3110
57. Z. Ghalanbor, M. Körber, and R. Bodmeier Interdependency of protein-release completeness and polymer degradation in PLGA-based implants Eur. J. Pharm. Biopharm. 2013 [ http://dx.doi.org/10.1016/j.ejpb.2013.03.031.]
58. J.R. DesNoyer, and A.J. McHugh The effect of Pluronic on the protein release kinetics of an injectable drug delivery system J. Control. Release 86 2003 15 24
59. M.L. Houchin, S.A. Neuenswander, and E.M. Topp Effect of excipients on PLGA film degradation and the stability of an incorporated peptide J. Control. Release 117 2007 413 420
60. M. Voigt, M. Koerber, and R. Bodmeier Improved physical stability and injectability of non-aqueous in situ PLGA microparticle forming emulsions Int. J. Pharm. 434 2012 251 256
61. W.Y. Dong, M. Koerber, V. Lopez Esguerra, and R. Bodmeier Stability of poly(d, l-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug delivery systems J. Control. Release 115 2006 158 167
62. R.C. Rowe, P.J. Sheskey, W.G. Cook, and M.E. Fenton Handbook of Pharmaceutical Excipients 7th edition 2012 Pharmaceutical Press London
63. W. Rungseevijitprapa, and R. Bodmeier Injectability of biodegradable in situ forming microparticle systems (ISM) Eur. J. Pharm. Sci. 36 2009 524 531
64. International conference on harmonisation Impurities: Guidelines for Residual Solvents, Q3C (R4) 2009
65. M. Okada Chemical syntheses of biodegradable polymers Prog. Polym. Sci. 27 2002 87 133
66. D.K. Gilding, and A.M. Reed Biodegradable polymers for use in surgery- polyglycolic/poly(lactic acid) homo-and copolymers:1 Polymer 20 1979 1459 1464
67. R.J. Fredericks, A.J. Melveger, and L.J. Dolegiewitz Morphological and structural changes in a copolymer of glycolide and lactide occurring as a result of hydrolysis J. Polym. Sci. 22 1984 57 66
68. S. Li Hydrolytic degradation characteristics of aliphatic polyesters derived from lactic and glycolic acids J. Biomed. Mater. Res. 48 1999 342 353
69. G. Schwach, and M. Vert In vitro and in vivo degradation of lactic acid-based interference screws used in cruciate ligament reconstruction Int. J. Biol. Macromol. 25 1999 283 291
70. J.R. DesNoyer, and A.J. McHugh Role of crystallization in the phase inversion dynamics and protein release kinetics of injectable drug delivery systems J. Control. Release 70 2001 285 294
71. T.G. Park Degradation of poly(lactic-co-glycolic acid) microspheres: effect of copolymer composition Biomaterials 16 1995 1123 1130
72. X.S. Wu, and N. Wang Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: biodegradation J. Biomater. Sci. Polym. Ed. 12 2001 21 34
73. R.B. Patel, A.N. Carlson, L. Solorio, and A.A. Exner Characterization of formulation parameters affecting low molecular weight drug release from in situ forming drug delivery systems J. Biomed. Mater. Res. A 94 2010 476 484
74. L. Solorio, A.M. Olear, J.I. Hamilton, R.B. Patel, A.C. Beiswenger, J.E. Wallace, H. Zhou, and A.A. Exner Noninvasive characterization of the effect of varying PLGA molecular weight blends on in situ forming implant behavior using ultrasound imaging Theranostics 2 2012 1064 1077
75. M.A. Tracy, K.L. Ward, L. Firouzabadian, Y. Wang, N. Dong, R. Qian, and Y. Zhang Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheres in vivo and in vitro Biomaterials 20 1999 1057 1062
76. S. Chhabra, V. Sachdeva, and S. Singh Influence of end groups on in vitro release and biological activity of lysozyme from a phase-sensitive smart polymer-based in situ gel forming controlled release drug delivery system Int. J. Pharm. 342 2007 72 77
77. K.Y. Cho, and S. Lee J-K. Park, In situ micro-sized gel-forming injectable implant using biodegradable amphiphilic graft copolymer Macromol. Biosci. 7 2007 784 788
78. G. Tae, J.A. Kornfield, and J.A. Hubbell Sustained release of human growth hormone from in situ forming hydrogels using self-assembly of fluoroalkyl-ended poly(ethylene glycol) Biomaterials 26 2005 5259 5266
79. W.J. Lambert, and K.D. Peck Development of an in situ forming biodegradable poly-lactide-co-glycolide system for the controlled release of proteins J. Control. Release 33 1995 189 195
80. X. Luan, and R. Bodmeier In situ forming microparticle system for controlled delivery of leuprolide acetate: influence of the formulation and processing parameters Eur. J. Pharm. Sci. 27 2006 143 149
81. S.H. Wang, Z.H. Liang, and S. Zeng Monitoring release of ketoprofen enantiomers from biodegradable poly(d, l-lactide-co-glycolide) injectable implants Int. J. Pharm. 337 2007 102 108
82. H.B. Ravivarapu, K.L. Moyer, and R.L. Dunn Parameters affecting the efficacy of a sustained release polymeric implant of leuprolide Int. J. Pharm. 194 2000 181 191
83. M. Körber, and R. Bodmeier Development of an in situ forming PLGA drug delivery system I. Characterization of a non-aqueous protein precipitation Eur. J. Pharm. Sci. 35 2008 283 292
84. L. Li, and S.P. Schwendeman Mapping neutral microclimate pH in PLGA microspheres J. Control. Release 101 2005 163 173
85. R.A. Jain, C.T. Rhodes, A.M. Railkar, A.W. Malick, and N.H. Shah Controlled release of drugs from injectable in situ formed biodegradable PLGA microspheres: effect of various formulation variables Eur. J. Pharm. Biopharm. 50 2000 257 262
86. M. Zare, H. Mobedi, J. Barzin, H. Mivehchi, A. Jamshidi, and R. Mashayekhi Effect of additives on release profile of leuprolide acetate in an in situ forming controlled-release system: In vitro study J. Appl. Polym. Sci. 107 2008 3781 3787
87. A. Mashak, H. Mobedi, F. Ziaee, and M. Nekoomanesh The effect of aliphatic esters on the formation and degradation behavior of PLGA-based in situ forming system Polym. Bull. 66 2011 1063 1073
88. G. Gyulai, C.B. Pénzes, M. Mohai, T. Lohner, P. Petrik, S. Kurunczi, and É. Kiss Interfacial properties of hydrophilized poly(lactic-co-glycolic acid) layers with various thicknesses J. Colloid Interface Sci. 362 2011 600 606
89. A.A. Exner, T.M. Krupka, K. Scherrer, and J.M. Teets Enhancement of carboplatin toxicity by Pluronic block copolymers J. Control. Release 106 2005 188 197
90. H. Kranz, and R. Bodmeier A novel in situ forming drug delivery system for controlled parenteral drug delivery Int. J. Pharm. 332 2007 107 114
91. R. Bodmeier, Multiphase system, European patent No. 996426 A1, 2000.
92. H. Kranz, G.A. Brazeau, J. Napaporn, R.L. Martin, W. Millard, and R. Bodmeier Myotoxicity studies of injectable biodegradable in-situ forming drug delivery systems Int. J. Pharm. 212 2001 11 18
93. J. Li, F. Chen, C. Hu, L. He, K. Yan, L. Zhou, and W. Pan Optimized preparation of in situ forming microparticles for the parenteral delivery of vinpocetine Chem. Pharm. Bull. 56 2008 796 801
94. R.G. Strickley Solubilizing excipients in oral and injectable formulations Pharm. Res. 21 2004 201 230
95. F. Mottu, A. Laurent, D.A. Rufenacht, and E. Doelker Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data J. Pharm. Sci. Technol. 54 2000 456 469
96. Food and Drug Administration New Animal Drug Application NADA 141-265 2008
97. W. Rungseevijitprapa, G.A. Brazeau, J.W. Simkins, and R. Bodmeier Myotoxicity studies of O/W-in situ forming microparticle systems Eur. J. Pharm. Biopharm. 69 2008 126 133
98. M.A. Royals, S.M. Fujita, G.L. Yewey, J. Rodriguez, P.C. Schultheiss, and R.L. Dunn Biocompatibility of a biodegradable in situ forming implant system in rhesus monkeys J. Biomed. Mater. Res. 45 1999 231 239
99. F. Kang, and J. Singh In vitro release of insulin and biocompatibility of in situ forming gel systems Int. J. Pharm. 304 2005 83 90
100. K. Schoenhammer, J. Boisclair, H. Schuetz, H. Petersen, and A. Goepferich Biocompatibility of an injectable in situ forming depot for peptide delivery J. Pharm. Sci. 99 2010 4390 4399
101. K. Schoenhammer, H. Petersen, F. Guethlein, and A. Goepferich Injectable in situ forming depot systems: PEG-DAE as novel solvent for improved PLGA storage stability Int. J. Pharm. 371 2009 33 39
102. K. Schoenhammer, H. Petersen, F. Guethlein, and A. Goepferich Poly(ethyleneglycol) 500 dimethylether as novel solvent for injectable in situ forming depots Pharm. Res. 26 2009 2568 2577
103. S. Kempe, H. Metz, P.G. Pereira, and K. Mader Non-invasive in vivo evaluation of in situ forming PLGA implants by benchtop magnetic resonance imaging (BT-MRI) and EPR spectroscopy Eur. J. Pharm. Biopharm. 74 2010 102 108
104. L.R. Asmus, R. Gurny, and M. Möller Solutions as solutions-synthesis and use of a liquid polyester excipient to dissolve lipophilic drugs and formulate sustained-release parenterals Eur. J. Pharm. Biopharm. 79 2011 584 591
105. L.R. Asmus, J.-C. Tille, B. Kaufmann, L. Melander, T. Weiss, K. Vessman, W. Koechling, G. Schwach, R. Gurny, and M. Möller In vivo biocompatibility, sustained-release and stability of triptorelin formulations based on a liquid, degradable polymer J. Control. Release 165 2013 199 206
106. R. Astaneh, M. Erfan, H. Moghimi, and H. Mobedi Changes in morphology of in situ forming PLGA implant prepared by different polymer molecular weight and its effect on release behavior J. Pharm. Sci. 98 2009 135 145
107. H. Ueda, M.C. Hacker, A. Haesslein, S. Jo, D.M. Ammon, R.N. Borazjani, J.F. Kunzler, J.C. Salamone, and A.G. Mikos Injectable, in situ forming poly(propylene fumarate)-based ocular drug delivery systems J. Biomed. Mater. Res. A 83 2007 656 666
108. N. Nasongkla, A. Boongird, S. Hongeng, C. Manaspon, and N. Larbcharoensub Preparation and biocompatibility study of in situ forming polymer implants in rat brains J. Mater. Sci. Mater. Med. 23 2012 497 505
109. T.M. Krupka, B.D. Weinberg, N.P. Ziats, J.R. Haaga, and A.A. Exner Injectable polymer depot combined with radiofrequency ablation for treatment of experimental carcinoma in rat Invest. Radiol. 41 2006 890 897
110. R.B. Patel, L. Solorio, H. Wu, T. Krupka, and A.A. Exner Effect of injection site on in situ implant formation and drug release in vivo J. Control. Release 2010 350 358
111. P.-E. Le Renard, F. Buchegger, A. Petri-Fink, F. Bosman, D. Rüfenacht, H. Hofmann, E. Doelker, and O. Jordan Local moderate magnetically induced hyperthermia using an implant formed in situ in a mouse tumor model Int. J. Hyperthermia 25 2009 229 239
112. S. Kempe, H. Metz, and K. Mader Do in situ forming PLG/NMP implants behave similar in vitro and in vivo? A non-invasive and quantitative EPR investigation on the mechanisms of the implant formation process J. Control. Release 130 2008 220 225
113. J.-M. Lü, X. Wang, C. Marin-Muller, H. Wang, P.H. Lin, Q. Yao, and C. Chen Current advances in research and clinical applications of PLGA-based nanotechnology Expert. Rev. Mol. Diagn. 9 2009 325 341
114. M. Qiao, D. Chen, X. Ma, and H. Hu Sustained release of bee venom peptide from biodegradable thermosensitive PLGA-PEG-PLGA triblock copolymer-based hydrogels in vitro Pharmazie 61 2006 199 202
115. S.A. Yehia, A.H. Elshafeey, and I. Elsayed A novel injectable in situ forming poly-DL-lactide and DL-lactide/glycolide implant containing lipospheres for controlled drug delivery J. Liposome Res. 22 2012 128 138